Finasteride 5 mg
Article Sidebar
Main Article Content
Abstract
Finasteride is a specific competitive inhibitor of 5α-reductase to reduce dihydrotestosterone (DHT) production. Finasteride is approved for treatment Symptomatic benign prostatic hyperplasia (BPH), Male hair loss, Benign prostatic hyperplasia-Hematuria (Unlabeled use), Hirsutism (Unlabeled use) and Prophylaxis prostate cancer (Unlabeled use). The common side effect is Erectile dysfunction, Loss of libido and Breast enlargement.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Ahmed OAA, Rizg W. Finasteride nano-transferosomal gel formula for management of androgenetic alopecia: ex vivo investigational approach. Drug Design, Development and Therapy 2018;12:2259-65.
Borst SE, Lowenthal DT, Zavros G. Androgen biosynthesis inhibitors and androgen receptor antagonists. In: Martini L, editors. Encyclopedia of endocrine diseases. Amsterdam: Elsevier; 2004. p.210-3.
Lexicomp. Drug information handbook 2012-2013: a comprehensive resource for all clinicians and healthcare professionals. 21st ed. Ohio: Lexicomp; 2012.
Mega Lifesciences. Rx prescription drug: Stercia-5 Finasteride tablets 5 mg. Samut Prakan: Mega Lifesciences; 2014.
Wilde MI, Goa KL. Finasteride: an update of its use in the management of symptomatic benign prostatic hyperplasia. Drugs 1999;57:557-81.
Edwards JE, Moore RA. Finasteride in the treatment of clinical benign prostatic hyperplasia: a systematic review of randomised trials. BMC Urol [Internet]. 2002 [cited 2023 June 30];2:14. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC140032/pdf/1471-2490-2-14.pdf